Adaptive Randomized study of idarubicin and cytarabine (IA) alone or with interleukin 11 (IL-11) as induction therapy in patients aged 50 or above with untreated acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (HR-MDS).

被引：0
|
作者：
Giles, F [1 ]
Kantarjian, H [1 ]
Cortes, J [1 ]
Tsimberidou, A [1 ]
Faderl, S [1 ]
Verstovsek, S [1 ]
Thomas, D [1 ]
Garcia-Manero, G [1 ]
Wierda, W [1 ]
Ferrajoli, A [1 ]
Kornblau, S [1 ]
Andreeff, M [1 ]
O'Brien, S [1 ]
Beran, M [1 ]
Estey, E [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4740
引用
收藏
页码：253B / 253B
页数：1
相关论文
共 50 条
  • [31] Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)
    Perez, Jorge M. Ramos
    Kadia, Tapan M.
    Montalban-Bravo, Guillermo
    Benton, Christopher B.
    Faderl, Stefan
    Sasaki, Koji
    Naqvi, Kiran
    Cortes, Jorge E.
    Daver, Naval G.
    DiNardo, Courtney D.
    Jabbour, Elias
    Borthakur, Gautam M.
    Al Azzawi, Hind
    Pemmaraju, Naveen
    Konopleva, Marina Y.
    Pierce, Sherry A.
    Jain, Nitin
    Ohanian, Maro
    Garcia-Manero, Guillermo
    Andreeff, Michael
    Kantarjian, Hagop M.
    Ravandi, Farhad
    Alvarado, Yesid
    BLOOD, 2019, 134
  • [32] Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study
    Ohtake, Shigeki
    Miyawaki, Shuichi
    Fujita, Hiroyuki
    Kiyoi, Hitoshi
    Shinagawa, Katsuji
    Usui, Noriko
    Okumura, Hirokazu
    Miyamura, Koichi
    Nakaseko, Chiaki
    Miyazaki, Yasushi
    Fujieda, Atsushi
    Nagai, Tadashi
    Yamane, Takahisa
    Taniwaki, Masafumi
    Takahashi, Masatomo
    Yagasaki, Fumiharu
    Kimura, Yukihiko
    Asou, Norio
    Sakamaki, Hisashi
    Handa, Hiroshi
    Honda, Sumihisa
    Ohnishi, Kazunori
    Naoe, Tomoki
    Ohno, Ryuzo
    BLOOD, 2011, 117 (08) : 2358 - 2365
  • [33] Results of a multicenter phase II trial for older patients with c-kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose ara-C and imatinib
    Heidel, Florian
    Cortes, Jorge
    Ruecker, Frank G.
    Aulitzky, Walter
    Letvak, Laurie
    Kindler, Thomas
    Huber, Christoph
    Doehner, Hartmut
    Kantarjian, Hagop
    Fischer, Thomas
    CANCER, 2007, 109 (05) : 907 - 914
  • [34] A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-tine therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome
    Faderl, Stefan
    Ravandi, Farhad
    Huang, Xuelin
    Garcia-Manero, Guillermo
    Ferrajoli, Alessandra
    Estrov, Zeev
    Borthakur, Gautarn
    Verstovsek, Srdan
    Thomas, Deborah A.
    Kwari, Monica
    Kantarjian, Hagop M.
    BLOOD, 2008, 112 (05) : 1638 - 1645
  • [35] Efficacy and safety of sabatolimab (MBG453) in combination with hypomethylating drugs (HMAs) in patients with very high or high risk myelodysplastic syndrome (vHR/HR-MDS) and acute myeloid leukemia (AML): final analysis after a phase Ib study
    Brunner, A.
    Porkka, K.
    Knapper, S.
    Traer, E.
    Scholl, S.
    Garcia-Manero, G.
    Vey, N.
    Wermke, M.
    Janssen, J.
    Narayan, R.
    Loo, S.
    Tovar, N.
    Kontro, M.
    Naidu, P.
    Pelletier, M.
    Steensma, D.
    Lewandowski, A.
    Zhang, N.
    Mohammed, A.
    Borate, U.
    Wei, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 35 - 36
  • [36] A randomized, placebo-controlled, double blind trial of the MDR modulator, zosuquidar, during conventional induction and post-remission therapy for pts > 60 years of age with newly diagnosed acute myeloid leukemia (AML) or high-risk Myelodysplastic syndrome (HR-MDS):: ECOG 3999.
    Cripe, Larry D.
    Li, Xiaochun
    Litzow, Mark
    Paietta, Elisabeth
    Rowe, Jacob M.
    Luger, Selina
    Tallman, Martin
    BLOOD, 2006, 108 (11) : 129A - 129A
  • [37] Results of a multicenter phase II trial for older patients with c-Kit positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C (LDAC) and imatinib.
    Heidel, F
    Cortes, J
    Ruecker, F
    Kaufmann, M
    Aulitzky, W
    Letvak, L
    Kindler, T
    Huber, C
    Dohner, H
    Kantarjian, H
    Fischer, T
    BLOOD, 2005, 106 (11) : 527A - 527A
  • [38] A phase II study of venetoclax (VEN) in combination with 10-day decitabine (DEC) in older/unfit pts with newly diagnosed (ND) or pts with relapsed/refractory (R/R) acute myeloid leukemia (AML), or high-risk myelodysplastic syndrome (HR-MDS).
    Swaminathan, Mahesh
    Dinardo, Courtney Denton
    Maiti, Abhishek
    Pemmaraju, Naveen
    Ohanian, Maro
    Daver, Naval Guastad
    Garcia-Manero, Guillermo
    Issa, Ghayas C.
    Borthakur, Gautam
    Ravandi-Kashani, Farhad
    Montalban-Bravo, Guillermo
    Kadia, Tapan M.
    Valero, Yesid Alvarado
    Jabbour, Elias
    Short, Nicholas James
    Wierda, William G.
    Jain, Nitin
    Kornblau, Steven Mitchell
    Kantarjian, Hagop M.
    Konopleva, Marina
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [39] A Phase I Study of CC-90002, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS): Final Results
    Zeidan, Amer M.
    DeAngelo, Daniel J.
    Palmer, Jeanne M.
    Seet, Christopher S.
    Tallman, Martin S.
    Wei, Xin
    Li, Ying Fei
    Hock, Nanette
    Burgess, Michael R.
    Hege, Kristen
    Stock, Wendy
    BLOOD, 2019, 134
  • [40] Sabatolimab Plus Hypomethylating Agents (HMAs) in Patients with High-/Very High-risk Myelodysplastic Syndrome (HR/vHR-MDS) and Newly Diagnosed Acute Myeloid Leukemia (ND-AML): Subgroup Analysis of a Phase 1 Study
    Garcia-Manero, Guillermo
    Wei, Andrew H.
    Porkka, Kimmo
    Knapper, Steve
    Traer, Elie
    Scholl, Sebastian
    Vey, Norbert
    Wermke, Martin
    Janssen, Jeroen
    Narayan, Rupa
    Loo, Sun
    Tovar, Natalia
    Kontro, Mika
    Ottmann, Oliver
    Naidu, Purushotham
    Orlando, Elena
    Patel, Nidhi
    Makofske, Jessica
    Ma, Fei
    Zhang, Na
    Mohammed, Anisa
    Rinne, Mikael L.
    Borate, Uma
    Brunner, Andrew M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S350 - S350
12345